Replies to post #159 on Provectus Biopharmaceuticals Inc (PVCT)

[Gulfbreeze]

Oh I don't plan on selling till this goes a lot further the potential is huge....

[Gulfbreeze]

Provectus Pharmaceuticals (PVCT) Breaks Out from 52-Week High

By Justin · Wednesday, February 24th, 2010

Provectus Pharmaceuticals, Inc. (PVCT), which is developing cancer therapies in the same fields as Dendreon Corporation (DNDN) and Genta Incorporated (GETA), broke out from its 52-week high during today’s session.

Provectus Pharmaceuticals, Inc. (PVCT), a biopharmaceutical company focused on developing cancer and psoriasis treatments using the Rose Bengal compound, broke out from its 52-week high today ahead of key clinical trial results.

Provectus announced updates to its Phase 2 trial data back in November 2009 and found that its PV-10 for the treatment of metastatic melanoma was safe and over a one year period. Moreover, PV-10 showed markedly longer overall and disease specific survival in subjects.

Subsequently, Provectus presented early results from its Phase 2 trial during the annual meeting of the American Society of Clinical Oncology (ASCO) in June of 2009. Researchers found that an objective response was seen in 60% of subjects with locoregional disease control in 75%.

Interestingly, Provectus also observed a “bystander effect” whereby untreated bystander lesions also responded to treatment. The company believes that Rose Bengal may induce the patient’s own immune system to attack and shrink untreated tumors.

Meanwhile, Provectus’ PH-10 for the treatment of psoriasis is also in late-stage clinical trials. The company announced Phase 2 trial results in December of 2009, and stated that it was looking to license the drug going forward with the help of a financial advisor.

With its PV-10 in ongoing trials and a compassionate use program underway and PH-10 in late-stage development, many investors are looking ahead to future results being announced, which could represent a very positive catalyst for the stock price going forward.

TheOTCInvestor.com has been compensated by CoroWare Inc. (COWI) as a part of a larger marketing campaign. Click here to view our disclaimer.

http://theotcinvestor.com/provectus-pharmaceuticals-pvct-breaks-out-from-52-week-high-634/